Carla Van Aller1, Jose Lara2, Blossom C M Stephan3, Lorenzo Maria Donini4, Steven Heymsfield5, Peter T Katzmarzyk5, Jonathan C K Wells6, Carla M Prado7, Mario Siervo8. 1. Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Campus for Ageing and Vitality, Newcastle on Tyne, NE4 5PL, UK. 2. Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, UK. 3. Institute of Health and Society, Newcastle University, Campus for Ageing and Vitality, Newcastle on Tyne, NE4 5PL, UK. 4. Department of Experimental Medicine- Medical Pathophysiology, Food Science and Endocrinology Section, Sapienza University of Rome, 00185 Rome, Italy. 5. Pennington Biomedical Research Center, Baton Rouge, LA, USA. 6. Childhood Nutrition Research Centre, Institute of Child Health, University College of London, 30 Guilford Street, WC1N 1EH, London, UK. 7. Department of Agriculture, Food and Nutritional Science, University of Alberta, Edmonton, AB, Canada. 8. Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Campus for Ageing and Vitality, Newcastle on Tyne, NE4 5PL, UK. Electronic address: mario.siervo@ncl.ac.uk.
Abstract
BACKGROUND/ OBJECTIVES: There is no consensus on the definition of sarcopenic obesity (SO), resulting in inconsistent associations of SO with mortality risk. We aim to evaluate association of dual energy x-ray absorptiometry (DXA) SO models with mortality risk in a US adult population (≥50 years). SUBJECTS/ METHODS: The study population consisted of 3577 participants aged 50 years and older from the 1999-2004 National Health and Nutrition and Examination Survey with mortality follow-up data through December 31, 2011. Difference in survival time in people with and without SO defined by three body composition DXA models (Model 1: body composition phenotype model; Model 2: Truncal Fat Mass (TrFM)/Appendicular Skeletal Muscle Mass (ASM) ratio model; Model 3: Fat Mass (FM)/Fat Free Mass (FFM) ratio). The differences between the models were assessed by the acceleration failure time model, and expressed as time ratios (TR). RESULTS: Participants age 50-70 years with SO had a significantly decreased survival time, according to the body composition phenotype model (TR: 0.92; 95% CI: 0.87-0.97), and TrFM/ASM ratio model (TR: 0.88; 95% CI: 0.81-0.95). The FM/FFM ratio model did not detect significant differences in survival time. Participants with SO aged 70 years and older did not have a significantly decreased survival time, according to all three models. CONCLUSIONS: A SO phenotype increases mortality risk in people of age 50-70 years, but not in people aged 70 years and older. The application of the body composition phenotype and the TrFM/ASM ratio models may represent useful diagnostic approaches to improve the prediction of disease and mortality risk.
BACKGROUND/ OBJECTIVES: There is no consensus on the definition of sarcopenic obesity (SO), resulting in inconsistent associations of SO with mortality risk. We aim to evaluate association of dual energy x-ray absorptiometry (DXA) SO models with mortality risk in a US adult population (≥50 years). SUBJECTS/ METHODS: The study population consisted of 3577 participants aged 50 years and older from the 1999-2004 National Health and Nutrition and Examination Survey with mortality follow-up data through December 31, 2011. Difference in survival time in people with and without SO defined by three body composition DXA models (Model 1: body composition phenotype model; Model 2: Truncal Fat Mass (TrFM)/Appendicular Skeletal Muscle Mass (ASM) ratio model; Model 3: Fat Mass (FM)/Fat Free Mass (FFM) ratio). The differences between the models were assessed by the acceleration failure time model, and expressed as time ratios (TR). RESULTS: Participants age 50-70 years with SO had a significantly decreased survival time, according to the body composition phenotype model (TR: 0.92; 95% CI: 0.87-0.97), and TrFM/ASM ratio model (TR: 0.88; 95% CI: 0.81-0.95). The FM/FFM ratio model did not detect significant differences in survival time. Participants with SO aged 70 years and older did not have a significantly decreased survival time, according to all three models. CONCLUSIONS: A SO phenotype increases mortality risk in people of age 50-70 years, but not in people aged 70 years and older. The application of the body composition phenotype and the TrFM/ASM ratio models may represent useful diagnostic approaches to improve the prediction of disease and mortality risk.
Authors: Meredith L Wallace; Daniel J Buysse; Susan Redline; Katie L Stone; Kristine Ensrud; Yue Leng; Sonia Ancoli-Israel; Martica H Hall Journal: J Gerontol A Biol Sci Med Sci Date: 2019-11-13 Impact factor: 6.053
Authors: Glaucia Cristina de Campos; Roberto Alves Lourenço; Maria Del Carmen Bisi Molina Journal: Rev Saude Publica Date: 2021-11-22 Impact factor: 2.106
Authors: David J Hanna; Scott T Jamieson; Christine S Lee; Christopher A Pluskota; Nicole J Bressler; Peter N Benotti; Sandeep Khurana; David D K Rolston; Christopher D Still Journal: Obes Sci Pract Date: 2021-05-06
Authors: Rebecca Knowles; Jennifer Carter; Susan A Jebb; Derrick Bennett; Sarah Lewington; Carmen Piernas Journal: J Am Heart Assoc Date: 2021-04-19 Impact factor: 5.501